Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 349

1.

Clinical and patient-reported outcomes in clinical trials of abatacept in the treatment of rheumatoid arthritis.

Massarotti EM.

Clin Ther. 2008 Mar;30(3):429-42. doi: 10.1016/j.clinthera.2008.03.002. Review.

PMID:
18405783
2.

Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus.

Sherrer Y.

Curr Med Res Opin. 2008 Aug;24(8):2283-94. doi: 10.1185/03007990802223129. Epub 2008 Jun 27. Review.

PMID:
18590608
3.

Improving patient outlook in rheumatoid arthritis: experience with abatacept.

Coughlin M.

J Am Acad Nurse Pract. 2008 Oct;20(10):486-95. doi: 10.1111/j.1745-7599.2008.00340.x. Review.

PMID:
19128344
4.

Role of abatacept in the management of rheumatoid arthritis.

Nogid A, Pham DQ.

Clin Ther. 2006 Nov;28(11):1764-78. Review.

PMID:
17212998
5.

Selective costimulation modulation with abatacept: a look at quality-of-life outcomes in patients with rheumatoid arthritis.

Shergy WJ.

Semin Arthritis Rheum. 2009 Jun;38(6):434-43. doi: 10.1016/j.semarthrit.2008.03.009. Epub 2008 Jun 9. Review.

PMID:
18538830
7.

Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment.

Russell AS, Wallenstein GV, Li T, Martin MC, Maclean R, Blaisdell B, Gajria K, Cole JC, Becker JC, Emery P.

Ann Rheum Dis. 2007 Feb;66(2):189-94. Epub 2006 Sep 19.

8.

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.

Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, Steinfeld S, Tindall E, Becker JC, Li T, Nuamah IF, Aranda R, Moreland LW.

Arthritis Rheum. 2005 Aug;52(8):2263-71. Erratum in: Arthritis Rheum. 2005 Oct;52(10):3321.

9.

Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life.

Emery P, Kosinski M, Li T, Martin M, Williams GR, Becker JC, Blaisdell B, Ware JE Jr, Birbara C, Russell AS.

J Rheumatol. 2006 Apr;33(4):681-9. Epub 2006 Mar 1.

PMID:
16568505
10.

Abatacept.

Hervey PS, Keam SJ.

BioDrugs. 2006;20(1):53-61; discussion 62. Review.

PMID:
16573350
11.

Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom.

Guyot P, Taylor PC, Christensen R, Pericleous L, Drost P, Eijgelshoven I, Bergman G, Lebmeier M.

J Rheumatol. 2012 Jun;39(6):1198-206. doi: 10.3899/jrheum.111345. Epub 2012 Apr 15. Review.

PMID:
22505698
12.

Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis.

Guyot P, Taylor P, Christensen R, Pericleous L, Poncet C, Lebmeier M, Drost P, Bergman G.

Arthritis Res Ther. 2011;13(6):R204. doi: 10.1186/ar3537. Epub 2011 Dec 12. Review.

13.

Safety profile of abatacept in rheumatoid arthritis: a review.

Khraishi M, Russell A, Olszynski WP.

Clin Ther. 2010 Oct;32(11):1855-70. doi: 10.1016/j.clinthera.2010.10.011. Review.

PMID:
21095481
14.

Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis.

Reynolds J, Shojania K, Marra CA.

Pharmacotherapy. 2007 Dec;27(12):1693-701. Review.

PMID:
18041889
15.

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.

Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, Li T, Schmidely N, Le Bars M, Dougados M.

Ann Rheum Dis. 2008 Apr;67(4):547-54. Epub 2007 Oct 5.

PMID:
17921185
16.

Abatacept for rheumatoid arthritis: a Cochrane systematic review.

Maxwell LJ, Singh JA.

J Rheumatol. 2010 Feb;37(2):234-45. doi: 10.3899/jrheum.091066. Epub 2010 Jan 15. Review. Erratum in: J Rheumatol. 2010 Mar;37(3):682.

PMID:
20080922
17.

Investigation into the impact of abatacept on sleep quality in patients with rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire Sleep Disturbance Scale.

Wells G, Li T, Tugwell P.

Ann Rheum Dis. 2010 Oct;69(10):1768-73. doi: 10.1136/ard.2009.119727. Epub 2010 Jul 7.

PMID:
20610444
18.

Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial.

Westhovens R, Cole JC, Li T, Martin M, Maclean R, Lin P, Blaisdell B, Wallenstein GV, Aranda R, Sherrer Y.

Rheumatology (Oxford). 2006 Oct;45(10):1238-46. Epub 2006 Mar 27.

PMID:
16567357
19.

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.

Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M.

N Engl J Med. 2005 Sep 15;353(11):1114-23. Erratum in: N Engl J Med. 2005 Nov 24;353(21):2311.

20.

Supplemental Content

Support Center